{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:31:44Z","timestamp":1790699504675,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clinthera.2025.04.010","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T07:08:04Z","timestamp":1747465684000},"page":"559-565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept\/Ranibizumab Versus Bevacizumab"],"prefix":"10.1016","volume":"47","author":[{"given":"Michelle Y.","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria L.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5557-2749","authenticated-orcid":false,"given":"Hamid","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.04.010_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001188","article-title":"Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII)","volume":"7","author":"Wang","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0002","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/24741264211028441","article-title":"Task Force on Intravitreal Injection Supplemental Services. Intravitreal injection therapy: current techniques and supplemental services","volume":"5","author":"Lam","year":"2021","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0003","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212532","article-title":"The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy","volume":"7","author":"Zhao","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40942-024-00537-5","article-title":"Comparison of antiangiogenic agents (ranibizumab, aflibercept, bevacizumab and ziv-aflibercept) in the therapeutic response to the exudative form of age-related macular degeneration according to the treat-and-extend protocol- true head-to-head study","volume":"10","author":"Kanadani","year":"2024","journal-title":"Int J Retina Vitr"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0005","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamaophthalmol.2019.3305","article-title":"Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion. A randomized clinical trial","volume":"137","author":"Hykin","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0006","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/jamaophthalmol.2015.4110","article-title":"American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice","volume":"134","author":"Heier","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0007","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa2204225","article-title":"DRCR Retina Network. Aflibercept monotherapy or bevacizumab first for diabetic macular edema","volume":"387","author":"Jhaveri","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.oret.2019.05.016","article-title":"Determinants in initial treatment choice for diabetic macular edema","volume":"4","author":"VanderBeek","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0009","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3928\/23258160-20210330-05","article-title":"Racial differences in anti-VEGF intravitreal injections among commercially insured beneficiaries","volume":"52","author":"Al-Moujahed","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0010","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.oret.2018.05.005","article-title":"Racial differences in age-related macular degeneration and associated anti-vascular endothelial growth factor intravitreal injections among Medicare beneficiaries","volume":"2","author":"Mahr","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0011","first-page":"1796","article-title":"Social determinants of health and selection of anti-VEGF agent for the treatment of branch retinal vein occlusion with cystoid macular edema","volume":"64","author":"Huang","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37880","article-title":"Factors associated with a patient\u2019s decision to select a cost-effective vs the most effective therapy for their own eye disease","volume":"4","author":"Malik","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0013","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/24741264231173771","article-title":"Socioeconomic disparities in patients receiving intravitreal injections for age-related macular degeneration amid the COVID-19 pandemic","volume":"7","author":"Nguyen","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0014","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.2147\/OPTH.S314840","article-title":"The impact of non-ophthalmic factors on intravitreal injections during the COVID-19 lockdown","volume":"15","author":"Ashrafzadeh","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0015","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMsr1809937","article-title":"The \u201cAll of Us\u201d research program","volume":"381","author":"Denny","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0016","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.oret.2024.01.017","article-title":"Disparities in retinal vein occlusion presentation and initiation of anti-VEGF therapy: an academy IRIS\u24c7 registry analysis","volume":"8","author":"Haller","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0017","first-page":"171","article-title":"Racial disparities in the screening and treatment of diabetic retinopathy","volume":"114","author":"Coney","year":"2022","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0018","first-page":"3961","article-title":"Factors predicting distribution and practice patterns of retina providers across the United States (US)","volume":"60","author":"Pandit","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0019","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ophtha.2013.10.037","article-title":"Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration","volume":"121","author":"Stein","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197670","article-title":"The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration\u2014a cost-effectiveness analysis from a societal perspective","volume":"13","author":"van Asten","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0021","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaophthalmol.2016.1669","article-title":"Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial","volume":"134","author":"Ross","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0022","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/09286586.2024.2310854","article-title":"Trends in anti-vascular endothelial growth factor original medicare part B claims in the United States, 2014-2019","volume":"31","author":"Desai","year":"2024","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0023","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2017.10.010","article-title":"Geographic and demographic variation in use of ranibizumab versus bevacizumab for neovascular age-related macular degeneration in the United States","volume":"184","author":"Gower","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2025.04.010_bib0024","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1097\/IAE.0000000000000182","article-title":"Retina specialists treating age-related macular degeneration recommend different approaches for patients than they would choose for themselves","volume":"34","author":"Jeng","year":"2014","journal-title":"Retina"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:03:34Z","timestamp":1762247014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825001298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0149291825001298"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept\/Ranibizumab Versus Bevacizumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}